Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | LDHB | P07195 | 10/20 | 0.51 |
| ▸ | LDHA | P00338 | 10/20 | 0.51 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.50 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.48 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.48 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.48 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.48 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.48 |
| ▸ | ATP1B3 | P54709 | 3/20 | 0.48 |
| ▸ | FXYD2 | P54710 | 3/20 | 0.48 |
| ▸ | ATP1A4 | Q13733 | 3/20 | 0.48 |
| ▸ | IDH1 | O75874 | 2/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3953538 | 1.00 | ALDH1A1 (0.55) | ALDH1A1HPGDLDHBLDHAGALR3 | |
| SCHEMBL481823 | 1.00 | ALDH1A1 (0.55) | ALDH1A1HPGDLDHBLDHAGALR3 | |
| SCHEMBL18449481 | 0.79 | ALDH1A1 (0.55) | ALDH1A1HPGDGALR3NR2F2ATP1A1 | |
| SCHEMBL19205648 | 0.79 | ALDH1A1 (0.55) | ALDH1A1HPGDGALR3NR2F2ATP1A1 | |
| SCHEMBL18483206 | 0.79 | ALDH1A1 (0.55) | ALDH1A1HPGDGALR3NR2F2ATP1A1 | |
| SCHEMBL482107 | 0.79 | LDHB (0.57) | LDHBLDHAGALR3NR2F2MAP4K4 | |
| SCHEMBL481775 | 0.79 | LDHB (0.57) | LDHBLDHAGALR3NR2F2MAP4K4 | |
| SCHEMBL481774 | 0.79 | LDHB (0.57) | LDHBLDHAGALR3NR2F2MAP4K4 | |
| SCHEMBL18448954 | 0.79 | LDHA (0.48) | ALDH1A1HPGDLDHBLDHAGALR3 | |
| SCHEMBL19205755 | 0.79 | LDHA (0.48) | ALDH1A1HPGDLDHBLDHAGALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2457913-B1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARM LLC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2090577-B1 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-8372976-B2 | Methods of treatment comprising the administration of heteroaryl compounds | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2457913-A2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2078016-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-06 | — | — | US | disclosed |
| US-7981893-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-07-19 | — | — | US | disclosed |
| EP-2090577-A2 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | Signal Pharmaceuticals LLC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2078016-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | disclosed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | JAK2, GLS2, NFKBIA | ALDH1A1 2178/4885HPGD 1554/4885LDHB 425/4885 |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, PHKG1, PHKG2 | ALDH1A1 1934/4885HPGD 1483/4885LDHB 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.